JP2023541458A5 - - Google Patents
Info
- Publication number
- JP2023541458A5 JP2023541458A5 JP2023516770A JP2023516770A JP2023541458A5 JP 2023541458 A5 JP2023541458 A5 JP 2023541458A5 JP 2023516770 A JP2023516770 A JP 2023516770A JP 2023516770 A JP2023516770 A JP 2023516770A JP 2023541458 A5 JP2023541458 A5 JP 2023541458A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- grna
- nuclease
- cell population
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078137P | 2020-09-14 | 2020-09-14 | |
| US63/078,137 | 2020-09-14 | ||
| PCT/US2021/050254 WO2022056459A1 (en) | 2020-09-14 | 2021-09-14 | Compositions and methods for cd5 modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541458A JP2023541458A (ja) | 2023-10-02 |
| JP2023541458A5 true JP2023541458A5 (https=) | 2024-09-25 |
Family
ID=78086070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516770A Abandoned JP2023541458A (ja) | 2020-09-14 | 2021-09-14 | Ｃｄ５修飾のための化合物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240041932A1 (https=) |
| EP (1) | EP4211245A1 (https=) |
| JP (1) | JP2023541458A (https=) |
| WO (1) | WO2022056459A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023251040A1 (en) * | 2022-04-04 | 2024-10-17 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| EP4587570A2 (en) * | 2022-09-16 | 2025-07-23 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
| EP4716744A2 (en) * | 2023-05-23 | 2026-04-01 | Vittoria Biotherapeutics, Inc. | Genetically modified cells comprising a heterologous nucleic acid molecule inserted at a cd5 gene locus field |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| WO2008121160A2 (en) | 2006-11-21 | 2008-10-09 | Xencor, Inc. | Optimized antibodies that target cd5 |
| RU2011111640A (ru) | 2008-08-29 | 2012-10-10 | Симфоген А/С (Dk) | Антитела против cd5 |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CA3048434A1 (en) | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| CN110944652A (zh) * | 2017-06-12 | 2020-03-31 | 爱莫里大学 | T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途 |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| EA202092044A1 (ru) | 2018-03-14 | 2021-03-03 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные рецепторы антигена против cd33 и их применения |
| EP3802798A4 (en) * | 2018-05-31 | 2022-05-11 | Washington University | CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER |
| WO2020014235A1 (en) * | 2018-07-09 | 2020-01-16 | The Regents Of The University Of California | Gene targets for t-cell-based immunotherapy |
| CA3107383A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| EP3911735A4 (en) * | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
| EP4034138A4 (en) * | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
-
2021
- 2021-09-14 WO PCT/US2021/050254 patent/WO2022056459A1/en not_active Ceased
- 2021-09-14 US US18/026,018 patent/US20240041932A1/en active Pending
- 2021-09-14 EP EP21789935.0A patent/EP4211245A1/en active Pending
- 2021-09-14 JP JP2023516770A patent/JP2023541458A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541457A5 (https=) | ||
| JP2023541458A5 (https=) | ||
| JP7625555B2 (ja) | 修飾されたガイドｒｎａ | |
| US20240084332A1 (en) | Reprogrammable tnpb polypeptides and use thereof | |
| US11639523B2 (en) | Type V CRISPR-Cas systems and use thereof | |
| JP6835726B2 (ja) | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 | |
| US20230392131A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| KR102699944B1 (ko) | Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법 | |
| CA3154236C (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| CN109207477B (zh) | Crispr酶以及系统 | |
| KR20180120752A (ko) | 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물 | |
| AU2016244033A1 (en) | CRISPR/CAS-related methods and compositions for treating Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | |
| US20240318165A1 (en) | Type i-b crispr-associated transposase systems | |
| JP2022534813A5 (https=) | ||
| US20220380758A1 (en) | Type i-b crispr-associated transposase systems | |
| JP2016501036A5 (https=) | ||
| US20250236857A1 (en) | Engineered chimeric iscb polypeptides and uses thereof | |
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| JP2024502820A5 (https=) | ||
| CN119193713A (zh) | 修饰的双链供体模板 | |
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| JP2024528202A5 (https=) | ||
| US20250223577A1 (en) | Hybrid crispr-cas systems and methods of use thereof | |
| CA3194645A1 (en) | Type i crispr-associated transposase systems | |
| WO2024260268A1 (zh) | 利用Cpf1非滞留端提高基因敲进效率和精准度的方法 |